


## Bromo-PEG2-C2-azide

<b>Cat. No.:</b>	HY-130485
<b>CAS No.:</b>	530151-56-5
<b>Molecular Formula:</b>	C <sub>6</sub> H <sub>12</sub> BrN <sub>3</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	238.08
<b>Target:</b>	ADC Linker; PROTAC Linkers
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related; PROTAC
<b>Storage:</b>	-20°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (420.03 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	<b>Preparing Stock Solutions</b>		1 mg	5 mg	10 mg
		1 mM	4.2003 mL	21.0013 mL	42.0027 mL
		5 mM	0.8401 mL	4.2003 mL	8.4005 mL
	10 mM	0.4200 mL	2.1001 mL	4.2003 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (10.50 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (10.50 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (10.50 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Bromo-PEG2-C2-azide is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Bromo-PEG2-C2-azide is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs <sup>[1]</sup> . Bromo-PEG2-C2-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.	
<b>IC<sub>50</sub> &amp; Target</b>	Non-cleavable Linker	PEGs
<b>In Vitro</b>	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.	

---

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Yong Zu Kim, et al. Antibody-drug conjugates comprising branched linkers and methods related thereto. WO2017089895A1.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA